We here present results indicating that, in the mouse lung LLC and mammary 4T1 cancer models, CD11c+ DC infiltrating tumors exhibit a semimature phenotype (intermediary expression of MHC-II, CD80, CD86, and CD83) and significantly suppress T lymphocyte activation in vitro by a mechanism involving CD39 ectoenzyme. This evidence concerns the gene CD86 and cancer.